The double-positive CD74/CD68 protein expression profile was still consistent with the expected concentration of patient-derived RECs of AML3 and is detectable as populations in newly diagnosed AML patients (Figures 3J and S4C, N = 25). This evidence concerns the gene RUNX2 and acute myeloid leukemia.